The global incidence of lung cancer is 1,608,800 per year, with an annual mortality rate of 1,378,400. It was the most commonly diagnosed cancer as well as the leading cause of cancer death in males globally, and among females, it was the fourth most commonly diagnosed cancer and the second leading cause of cancer death[@b1]. About 85% to 90% of lung cancers are non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, large cell carcinoma and other subtypes.

Epidemiological data have shown that environmental exposures such as tobacco smoking and asbestos are the main etiological factors in lung carcinogenesis[@b2][@b3]. However, only a small fraction of people, who are exposed to such risk factors, will develop lung cancer. This indicates that an individual\'s susceptibility might play a certain role in lung carcinogenesis. Recently, increasing evidence has been accumulated to support the hypothesis that common genetic variations of drug-metabolizing enzyme genes may be of importance in determining an individual\'s sensitivity to develop lung cancer[@b4].

Glutathione S-transferases (GSTs) are a group of phase II detoxification enzymes which detoxify a broad range of compounds, including xenobiotics, pesticides, products of oxidative stress, chemotherapeutic drugs and carcinogens such as benzo(a)pyrene and other polycyclic aromatic hydrocarbons[@b5]. Glutathione S-transferase mu-1 (GSTM1) is a polymorphic member of the mu class gene family of the GSTs. GSTM1 deletion polymorphism has been shown to result in the elimination of the activity of GSTM1 enzymes and modulate lung cancer risk[@b6]. To date, results from epidemiological studies on the association between GSTM1 deletion polymorphism and lung cancer risk in Chinese population have been mixed[@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59]. Recently, two meta-analyses have reported the association of GSTM1 deletion polymorphism with increased lung cancer risk in Chinese population[@b60][@b61]. Unfortunately, some overlapping articles were not excluded and several published papers were missing in their papers. In order to obtain a more precise estimation of this relationship, a meta-analysis including a total of 53 studies was conducted, which may provide more comprehensive evidence for the association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population.

Methods
=======

Literature and methods
----------------------

Systematic searches were performed in Medline/Pubmed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Wanfang Medical Online, with the following terms utilized: "lung cancer" or "lung tumor" or "lung carcinoma" or "non-small cell lung cancer" or "small cell lung cancer" and "polymorphism" and "GSTM1" and "Chinese" or "China". All publications were updated to July 15, 2014. Additional relevant references quoted in the searched articles were also selected.

Criteria of literature inclusion were (a) the subjects of literature must be Chinese; (b) the papers should evaluate the association of GSTM1 deletion polymorphism with lung cancer risk; (c) case-control studies or cohort studies; (d) studies should have sufficient data for estimating odds ratio (OR) with 95% confidence intervals (CI). The exclusion criteria were (a) studies without the number of case and control or other essential information and (b) reviews and repeated or overlapping studies. For repeated studies or overlapping studies, the publication with more information was selected when more than one article was identified for the same study population.

In total, ninety eight published articles were identified with the association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population. We reviewed all papers according to the criteria listed, above; forty one overlapping studies and four reviews were excluded. At last, fifty three original articles that focused on the association between GSTM1 deletion polymorphism and lung cancer risk in Chinese population were determined to be eligible to enter our study ([Fig. 1](#f1){ref-type="fig"} Flow diagram).

Data extraction
---------------

Data were carefully extracted from all selected articles by two of the authors, independently. The following information was subtracted from selected studies: author\'s name, publishing date, area, source of control, number of case and control, and number of null and present genotypes. Data coming from similar stratum were combined to make full use of them if the study provided stratum information. Characteristics of selected studies were summarized in [Table 1](#t1){ref-type="table"}.

Quantitative data synthesis
---------------------------

The strength of the association between GSTM1 deletion polymorphism and lung cancer risk was measured by OR with 95%CI. The Cochrane *Q* statistics test was used to assess heterogeneity. The combined OR was estimated using both a fixed-effects model and a random-effects model[@b62]. The fixed-effects model was used when there was lack of heterogeneity. Otherwise, the random-effects model was used. The potential publication bias was firstly evaluated by visual inspection of the funnel plot. An asymmetric plot indicates that a possible publication bias exists. The funnel plot asymmetry was evaluated by the methods of Egger\'s test and Begg\'s test[@b63][@b64].

Statistical analysis was done using Review Manager (Version 5.0.24, the Cochrane Collaboration) and STATA10.0 software package (Stata Corporation, College Station, Texas). All the tests were two-sided, a *P* value of less than 0.05 for any test or model was considered to be statistically significant.

Results
=======

Meta-analysis databases
-----------------------

A database was built in the light of the extracted information from selected articles. Some essential information was listed in [Table 1](#t1){ref-type="table"}, which indicated the first author\'s name, year of publication, area, source of control, the number of case and control, and stratified factors. There were a total of 53 studies with 7,833 cases and 10,353 controls concerning the GSTM1 deletion polymorphism related to lung cancer risk. The frequency of GSTM1 null genotype was 57.7% and 50.1% in case and control, respectively.

Test of heterogeneity
---------------------

The heterogeneity of GSTM1 null genotype vs. present genotype was analyzed for 53 selected studies. The results showed that GSTM1 null genotype vs. present genotype for squamous cell carcinoma, hospitalized patients-based control, smokers and nonsmokers had no heterogeneity with a *P* value ≥0.05. Therefore, a fixed-effects model was used to calculate the summary ORs for them. A random-effects model was used to calculate the summary ORs for the rest.

Quantitative data synthesis
---------------------------

[Table 2](#t2){ref-type="table"} listed the summary ORs of GSTM1 deletion polymorphism related to lung cancer risk in Chinese population on the basis of 7,833 cases and 10,353 controls. We observed an association of GSTM1 deletion polymorphism with increased lung cancer risk in the total population (OR = 1.46, 95%CI: 1.32--1.61 for null vs. present) ([Fig. 2](#f2){ref-type="fig"}). In subgroup analysis for source of control, we observed an increased risk of lung cancer with GSTM1 null genotype in healthy subjects-based control (OR = 1.48, 95%CI: 1.32--1.66) and hospitalized patients-based control (OR = 1.40, 95%CI: 1.22--1.60), respectively. We also observed an increased risk of GSTM1 null genotype for lung cancer stratified by smoking status (OR = 1.60, 95%CI: 1.41--1.81 for smokers and OR = 1.79, 95%CI: 1.54--2.08 for nonsmokers, respectively). We observed an association between GSTM1 null genotype and increased lung cancer risk in stratified analysis by histological type (OR = 1.50, 95%CI: 1.31--1.72 for squamous cell carcinoma and OR = 1.36, 95%CI: 1.08--1.70 for adenocarcinoma, respectively) ([Table 2](#t2){ref-type="table"}).

Bias diagnosis
--------------

Funnel plot was used to assess the publication bias, the shape of funnel plot seemed to be approximately symmetrical ([Fig. 3](#f3){ref-type="fig"}). Results from Egger\'s test and Begg\'s test indicated that no obvious publication bias existed in this meta-analysis ([Table 2](#t2){ref-type="table"}).

Sensitivity analysis
--------------------

The sensitivity analysis was performed to determine the influence of the individual dataset on the summary ORs by consecutively excluding individual studies. The overall effects were not changed significantly when the study was homogenous for GSTM1 null genotype vs. present genotype among total population by removing some eligible studies, indicating that our results were statistically robust ([Fig. 4](#f4){ref-type="fig"}).

Discussion
==========

GSTM1 gene is located on the short arm of chromosome 1 (1p13.3)[@b65]. It is 5,950 bp long consisting of seven introns and eight exons, which encodes a cytosolic protein of 218 amino acid residues with a molecular weight of 21/25 kDa. GSTM1 gene has a null variant allele, which results in an absence of enzyme activity. Individuals who carry homozygous deletions in this gene are thought to be increased risks for malignancies because of their reduced capacity to detoxify potential carcinogens[@b66][@b67]. In addition, GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients[@b68]. Some meta-analyses explored the association of GSTM1 null genotype with the development of several kinds of cancers in Chinese population[@b69][@b70][@b71][@b72]. In this paper, we performed a systematic literature review to comprehensively evaluate the association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population. We also evaluated the possible effect modifications by source of control, smoking status and histological subtype. The frequency of GSTM1 null genotype was 57.7% (range: 34%\~76.7%) and 50.1% (range: 14%\~66.4%) in case and control, respectively. The highest frequency of GSTM1 null genotype (66.4%) in control was found in Beijing[@b38] and the lowest frequency of GSTM1 null genotype (14%) in control was found in Yunnan[@b55]. In summary, we observed an increased lung cancer risk in subjects with GSTM1 null genotype. Two previous meta-analyses have reported the association of GSTM1 deletion polymorphism with increased lung cancer risk in Chinese population[@b60][@b61]. However, there are some key limitations in their studies. For example, three overlapping studies[@b73][@b74][@b75] were not properly excluded from Shi et al\' study and seven papers published before 2006[@b13][@b16][@b41][@b42][@b43][@b54][@b56] were missing. For Liu et al\' paper, eighteen overlapping papers[@b74][@b76][@b77][@b78][@b79][@b80][@b81][@b82][@b83][@b84][@b85][@b86][@b87][@b88][@b89][@b90][@b91][@b92] were not properly excluded. Therefore, the findings from these two meta-analyses should be clarified urgently by using the updated data. The present meta-analysis of 53 published studies including 7,833 cases and 10,353 controls might present a precise estimation of the association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population, owing to including the updated data.

Considering that cigarette smoking is an evident risk factor for lung cancer, and that GSTM1 is involved in the metabolism of various carcinogens present in cigarette smoking, a subgroup analysis regarding smoking status was conducted. After being stratified by smoking status, the GSTM1 null genotype was associated with an increased risk of lung cancer in both smokers and nonsmokers.

Lung cancer consists of at least three major histological subtypes: squamous cell carcinoma, adenocarcinoma and small cell carcinoma. It is well-known that the development of squamous cell carcinoma and small cell carcinoma is strongly correlated with cigarette smoking, whereas that of adenocarcinoma is less correlated compared with those two subtypes, which indicates that carcinogenic processes are different among the different subtypes of lung cancer[@b93]. Therefore, a stratified analysis was conducted by histological subtype. We observed significant associations of GSTM1 deletion polymorphism with the increased risk of both squamous cell carcinoma and adenocarcinoma. Further stratified analyses were not done in additional histological subtypes, since the sample size for them was relatively small.

This meta-analysis should be interpreted within the context of its potential limitations. First, the combined ORs were based on individual unadjusted estimates, while a more precise analysis depending on adjusted factors should be performed if detailed individual data were available. Secondly, only published papers were enrolled in this study, which may cause publication bias. To address this issue, Egger\'s test and Begg\'s test were conducted at the same time. Our findings demonstrated that the likelihood of key publication bias might not be present in this meta-analysis. Thirdly, each study had different eligibility criteria for subjects and different source of controls, which should be taken into account while expounding the combined effects. When subgroup analysis was performed by source of control, we observed an association between GSTM1 deletion polymorphism and increased lung cancer risk in both healthy subjects-based control and hospitalized patients-based control.

In conclusion, this comprehensive review demonstrates that GSTM1 null genotype might be a risk factor for lung cancer in the Chinese population. Large scale studies with the pooling of individual study data should be taken into consideration in the future studies to verify the results from this present meta-analysis.

Author Contributions
====================

Conceived and designed the experiments: W.Y. and Y.H.; Performed the experiments: Y.S., S.F. and W.H.; Analyzed the data: Y.H. and L.J.; Contributed reagents/material/analysis tools: Y.S., S.F. and W.H.; Wrote the main manuscript text: W.Y. and Y.H.; Reference collection and data management: L.J. and Y.S.; Statistical analyses and paper writing: Y.H. and W.Y.; Study design: W.Y. and Y.H.; Prepared figures 1--4: W.H.; All authors reviewed the manuscript.

![Flow diagram of selection process.](srep09392-f1){#f1}

![Forest plot of odds ratio for GSTM1 deletion polymorphism associated with lung cancer risk in Chinese population.](srep09392-f2){#f2}

![Funnel plot analysis to detect publication bias for GSTM1 deletion polymorphism associated with lung cancer risk in Chinese population.](srep09392-f3){#f3}

![Sensitivity analysis for GSTM1 null genotype vs. present genotype in Chinese population.](srep09392-f4){#f4}

###### Studies on the association between GSTM1 deletion polymorphism and lung cancer risk in Chinese population included in this study

  Author               Year             Area                          Source of control                Number of case   Number of control           Stratified factors
  ------------------- ------ --------------------------- -------------------------------------------- ---------------- ------------------- ------------------------------------
  Ai C[@b7]            2011            Sichuan                         Healthy subjects                      50                50                            
  Chan EC[@b8]         2005            Taiwan                          Healthy subjects                      75                162                         Sex
  Chan Y[@b40]         2002            Yunnan                          Healthy subjects                      56                99                            
  Chan-Yeung M[@b9]    2004           Hong Kong                        Healthy subjects                     229                197                  Histological type
  Chen CM[@b10]        2012           Zhejiang                         Healthy subjects                     200                189                       Smoking
  Chen H[@b11]         2008             Anhui                          Healthy subjects                     158                454                       Smoking
  Chen HC[@b12]        2006             Hunan                          Healthy subjects                      97                197                           
  Chen LJ[@b13]        2003             Anhui                          Healthy subjects                      38                99                        Smoking
  Chen SQ[@b14]        2001             Hubei                          Healthy subjects                     106                106                   Smoking and age
  Cheng YW[@b15]       2000            Taiwan                       Hospitalized patients                    73                33                            
  Dong CT[@b16]        2004            Sichuan                      Hospitalized patients                    82                91                            
  Du GB[@b17]          2011            Sichuan                      Hospitalized patients                   125                125            Histological type and smoking
  Fowke JH[@b18]       2011           Shanghai                         Healthy subjects                     208                785                           
  Gao Y[@b19]          1999           Guangdong           Hospitalized patients and healthy subjects         59                132            Histological type and smoking
  Ge H[@b20]           1996           Hongkong            Hospitalized patients and healthy subjects         89                53                            
  Gu YF[@b21]          2007            Beijing            Hospitalized patients and healthy subjects        279                684            Histological type and smoking
  Huang XH[@b22]       2004           Guangdong           Hospitalized patients and healthy subjects         85                138            Histological type and smoking
  Jiang XY[@b23]       2014        Inner Mongolia                      Healthy subjects                     180                266                           
  Lan Q[@b24]          2004            Yunnan                          Healthy subjects                     122                122                           
  Lei FM[@b25]         2007            Sichuan                         Healthy subjects                      42                103                 Smoking and drinking
  Li DR[@b26]          2005            Sichuan                      hospitalized patients                    99                66                        Smoking
  Li WY[@b27]          2012            Beijing                         Healthy subjects                     217                200                       Smoking
  Li Y[@b28]           2006             Henan                          Healthy subjects                      98                138            Histological type and smoking
  Liang GY[@b29]       2004            Jiangsu                      Hospitalized patients                   152                152                  Histological type
  Liang KC[@b30]       2012            Guangxi                      Hospitalized patients                    68                70                            
  Liu DZ[@b31]         2012         Heilongjiang                       Healthy subjects                     360                360            Histological type and smoking
  Liu Q[@b32]          2008           Shandong                         Healthy subjects                     110                125                           
  London SJ[@b33]      2000           Shanghai                         Healthy subjects                     232                710                           
  Lu QK[@b34]          2013           Guangdong                        Healthy subjects                      91                138            Histological type and smoking
  Luo CL[@b35]         2004           Guangdong                        Healthy subjects                      63                47                            
  Lv W[@b36]           2002            Beijing                         Healthy subjects                     314                314            Histological type and smoking
  Pan CG[@b37]         2014            Jiangxi                         Healthy subjects                     523                523          Histological type, smoking and sex
  Persson I[@b38]      1999            Beijing                         Healthy subjects                      75                119                           
  Qian BY[@b39]        2006            Tianjin                         Healthy subjects                     108                108                       Smoking
  Qiao GB[@b41]        2005           Guangdong           Hospitalized patients and healthy subjects        213                199                       Smoking
  Qu YH[@b42]          1998   Shanghai and Heilongjiang                Healthy subjects                     182                179                           
  Shi Y[@b43]          2002             Hubei                       Hospitalized patients                   120                120                           
  Sun GF[@b44]         1997           Liaoning                         Healthy subjects                     207                364                 Smoking, age and sex
  Wang JW[@b45]        2003            Beijing                         Healthy subjects                     164                181                       Smoking
  Wang MJ[@b46]        2009        Inner Mongolia                      Healthy subjects                     304                316                           
  Wang N[@b47]         2012             Henan                          Healthy subjects                     209                256                           
  Wang QM[@b48]        2006             Hubei                          Healthy subjects                      56                42                        Smoking
  Xia Y[@b49]          2008             Gansu                       Hospitalized patients                    58                116                       Smoking
  Yang XH[@b50]        2004           Liaoning                         Healthy subjects                     186                139                           
  Yao W[@b51]          2006             Henan                          Healthy subjects                      77                107                  Histological type
  Yao ZG[@b52]         2012            Beijing                         Healthy subjects                     150                150                       Smoking
  Zhang HY[@b53]       2014            Yunnan                          Healthy subjects                     110                100                           
  Zhang JK[@b54]       2002           Guangdong                        Healthy subjects                     161                165            Histological type and smoking
  Zhang JQ[@b55]       2011            Yunnan                          Healthy subjects                      50                50                        Smoking
  Zhang LZ[@b56]       2002            Jiangsu                         Healthy subjects                      65                60             Histological type and smoking
  Zhao B[@b57]         2001           Singapore                     Hospitalized patients                   233                187                           
  Zheng DJ[@b58]       2010            Tianjin                         Healthy subjects                     265                307                  Histological type
  Zhu XX[@b59]         2010             Hunan                          Healthy subjects                     160                160                           

###### Summery odds ratios on the relation of the GSTM1 deletion polymorphism to lung cancer risk in Chinese population

  Null vs. Present                       Case/Control   Heterogeneity test   Summery OR (95% CI)    Hypothesis test           Begg\'s test   Egger\'s test                        
  ------------------------------------- -------------- -------------------- --------------------- ------------------- ------ -------------- --------------- ------ ------- ------ -------
  All studies                             7833/10353          123.12              \<0.00001        1.46 (1.32--1.61)   7.40    \<0.00001          52         1.53   0.127   1.79   0.079
  Stratification by source of control                                                                                                                                                 
  Healthy subjects                        6459/8420           108.7               \<0.00001        1.48 (1.32--1.66)   6.56    \<0.00001          41         1.82   0.069   1.94   0.059
  Hospitalized patients                   1735/1933           14.88                 0.31           1.40 (1.22--1.60)   4.77    \<0.00001          13         0.07   0.945   0.67   0.517
  Stratification by smoking status                                                                                                                                                    
  Yes                                     2284/2078           22.38                 0.44           1.60 (1.41--1.81)   7.48    \<0.00001          22         0.05   0.958   0.50   0.620
  No                                      1468/2260           26.58                 0.11           1.79 (1.54--2.08)   7.58    \<0.00001          19         1.27   0.205   1.39   0.180
  Stratification by histological Type                                                                                                                                                 
  Squamous cell carcinoma                 1218/3375           15.96                 0.25           1.50 (1.31--1.72)   5.89    \<0.00001          13         0.00   1.000   0.40   0.694
  Adenocarcinoma                          1150/3368           28.44                 0.008          1.36 (1.08--1.70)   2.66      0.008            13         0.99   0.324   0.79   0.443
